Two-Drug Lung Cancer Treatment Study
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two experimental drugs (AMT-116 and ivosidan) for patients with advanced lung cancer that cannot be removed by surgery. The study aims to see if this combination can help shrink tumors and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with advanced (stage III or IV) non-small cell lung cancer that cannot be surgically removed
- Age between 18 and 75 years
- Good overall health and ability to care for yourself (ECOG performance status 0–1)
- At least one measurable tumor visible on imaging scans
- Expected to survive at least 12 weeks
- Willing to use effective contraception for at least 12 weeks after treatment ends
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two experimental drugs, AK146D1 and AK112, for people with advanced non-small cell lung cancer that cannot be removed by surgery or treated with standard chemo-radiation. It aims to find out if this combination can shrink tumors or slow cancer growth.
This trial tests a new drug, SHR-A2102, combined with other treatments for people with non-small cell lung cancer that can be removed with surgery. It aims to improve outcomes by using multiple therapies together.
This trial tests a combination of radiation therapy, chemotherapy, and two newer cancer-fighting drugs (tislelizumab and surufatinib) for patients with Stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment.
This early-stage trial tests a new drug combination (HS-20122) for non-small cell lung cancer that has spread or cannot be surgically removed. You may qualify if your cancer has progressed despite prior treatment or you haven't received prior treatment yet.
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
This trial tests a new drug called AMT-116 against a standard chemotherapy (docetaxel) for people with advanced non-squamous lung cancer that has gotten worse after previous treatments. The goal is to see which works better.
Hear when a new Advanced Non-small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.